1315results about "Antibacterial agents" patented technology

This invention relates to the field of nursing gel technology, and discloses a moisturizing nursing gel and its preparation method. The nursing gel is prepared from deionized water, poloxamer 407 powder, β-glucan, an antibacterial composite particle dispersion, and an aqueous lactic acid solution. The antibacterial composite particle dispersion is prepared from chitosan, an aqueous acetic acid solution, an antibacterial moisturizer, a modified sodium alginate solution, and deionized water. The modified sodium alginate solution is prepared from an aqueous sodium alginate solution, an aqueous sodium hydroxide solution, dopamine hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and deionized water. The antibacterial moisturizer is prepared from sodium hyaluronate, fructooligosaccharides, deionized water, polyhexamethylene biguanide hydrochloride, sodium pyrrolidone carboxylate, triethanolamine, sodium lactate, and an aqueous solution of 1,4-butanediol diglycidyl ether. This invention exhibits good antibacterial and moisturizing properties.

Disclosed herein is a compound that is (R)-(2-(3-((((2-ethylbutanoyl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propionamidoethyl)boronic acid citrate coordination complex, or a pharmaceutically acceptable salt or solvate thereof. Also disclosed herein are methods of treating a bacterial with a compound that is (R)-(2-(3-((((2-ethylbutanoyl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propionamidoethyl)boronic acid citrate coordination complex, or a pharmaceutically acceptable salt or solvate thereof in combination with ceftibuten.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

A polymer dot includes a nitrogen-containing carbon dot that is free of benzene rings. A preparation method of the polymer dot includes: treating an A2 type monomer and a Bs type monomer by a one-pot synthesis to obtain the polymer dot. A use of the polymer dot is for manufacture of at least one of anti-inflammatory, antibacterial, and antioxidant compositions.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

In certain aspects, the invention provides methods and compositions for heritable immunization and their use in infectious disease control. The invention also provides methods of preparing organisms and model organisms that can heritably transfer immunization to offspring.

This invention belongs to the technical field of medical disinfectant products, specifically relating to a medical agarwood extract disinfectant, its preparation method, and its application. The disinfectant is an oil-in-water microemulsion comprising agarwood supercritical CO2 extract (total sesquiterpenes mass fraction not less than 35%), a nonionic surfactant, a pH buffer, and water for injection. The pH value is 6.5-7.0, and the total sesquiterpenes concentration is not less than 5 mg / mL. The preparation method involves supercritical CO2 extraction of agarwood to obtain a lipid-soluble extract rich in sesquiterpenes, followed by high-pressure homogenization with a nonionic surfactant in a pH buffer to form a microemulsion. This invention achieves sterilization through membrane perturbation mechanisms using agarwood sesquiterpenes, without involving protein denaturation or strong oxidation, resulting in zero irritation to wounds. Its antibacterial efficacy is comparable to 75% ethanol. Sodium hyaluronate provides sustained-release protection and promotes healing, making it suitable for disinfection of surgical incisions, burns, and chronic ulcers.

The present application relates to the technical field of medicine, in particular to a Rubus corchorifolius S. Moore polysaccharide, a preparation method and application thereof. The Rubus corchorifolius S. Moore polysaccharide is obtained by extraction and purification from Rubus corchorifolius S. Moore by a limited method, has excellent biocompatibility, and has antibacterial and wound healing promotion effects, and therefore can be used for preparing a wound healing promotion drug. Specifically, the Rubus corchorifolius S. Moore polysaccharide has certain antibacterial properties on Escherichia coli and Staphylococcus aureus; the Rubus corchorifolius S. Moore polysaccharide can promote fibroblast proliferation in the proliferation stage of wound healing, promote the synthesis and deposition of type I collagen and the ordered remodeling of type III collagen in the remodeling stage; in addition, the Rubus corchorifolius S. Moore polysaccharide can effectively reduce the inflammatory response and pro-inflammatory immune activation of a wound by inhibiting the secretion of pro-inflammatory factor IL-6 and the expression of M1 macrophage marker CD86, and further regulate the wound inflammatory microenvironment and promote wound healing.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present invention relates to the field of biological fermentation application technology, and in particular, to use of a milk peptide fermentation product in regulating skin microecological balance. The milk peptide fermentation product selectively regulates the growth of Staphylococcus epidermidis and inhibits the growth of Staphylococcus aureus and Escherichia coli. It was discovered for the first time that the milk peptide fermentation product has a selective bacteriostatic effect on skin microorganisms. The experimental results show that the milk peptide fermentation product has an inhibitory effect on Escherichia coli and Staphylococcus aureus, but has no effect on the normal growth of Staphylococcus epidermidis. This characteristic is obviously different from common broad-spectrum chemical bacteriostatic agents, and the use of the milk peptide fermentation product is more conducive to maintaining the balance of skin microbiota.

The present application belongs to the technical field of daily chemical preparation, and particularly relates to a gynecological gel for inhibiting bacteria, regulating microecological balance and tightening vagina and a preparation method thereof. The gynecological gel comprises the following raw materials in mass fractions: 0.5-1 parts of carbomer, 0.04-0.09 parts of sodium hydroxide, 1-3 parts of collagen, 0.01-0.06 parts of sodium hyaluronate, 0.5-1.5 parts of isomaltooligosaccharide, 2-5 parts of propylene glycol, 0.05-0.3 parts of hydroxybenzoic acid methyl ester, 0.02-0.15 parts of hydroxyphenyl ethyl ester, 0.1-1.5 parts of hydrogenated lecithin, 1-6 parts of 1,3-butanediol, 3-5 parts of glycerol, 0.5-1 part of xanthan gum and 70-90 parts of water. The present application uses buckwheat filtrate to prepare collagen, and the active ingredients in the buckwheat filtrate can penetrate the cell membrane of pathogenic bacteria to play an antibacterial role; the collagen can repair the vaginal mucosa barrier and reduce the adhesion and invasion of pathogenic bacteria; therefore, after being compounded with the raw materials such as carbomer, sodium hydroxide, sodium hyaluronate, isomaltooligosaccharide and propylene glycol, the multiple components can synergistically promote the synthesis and repair of collagen fibers and improve the elasticity of tissues.

The present invention relates to a novel alarmin / PRR-targeting system using a TLR4 / MD2 / RAGE-targeting peptide (TMR peptide) derived from HMGB1, PTX3-TLR4 / MD2, or RAGE-interacting domains. The TMR peptide was further functionalized by conjugation with a liposomal delivery system (TMR-Lipo) to improve its unfavorable pharmacokinetic properties. It was demonstrated through the present invention that the TMR-Lipo suppressed TLR4- and RAGE-mediated inflammation by blocking the alarmin-PRR axis in LPS-treated macrophages. Most importantly, the combination of TMR-lipo and antibiotics, which possess both immunomodulatory and antimicrobial capacities, significantly affected the survival of CLP-induced septic mice by targeting the alarmin-PRR axis, thereby mitigating exacerbated inflammation. This synergistic therapeutic approach involving antibiotics and TMR-lipo has great promise as a therapeutic strategy for sepsis.

The invention relates to the field of food, in particular to a yeast beta-glucan composition for preventing and relieving upper respiratory tract infection. The composition provided by the invention mainly takes yeast beta-glucan and lactoferrin as main raw materials, and comprises the following components in percentage by weight: 0.1 to 80 percent of yeast beta-glucan and 0.1 to 80 percent of lactoferrin. The composition provided by the invention can also be prepared from other selective synergistic components and auxiliary materials through a series of processing technologies. The composition provided by the invention can ensure the complete structure and activity of the effective components, and has the effects of boosting immunity and preventing and relieving upper respiratory tract infection.

Methods for treating injuries to the central nervous system with a cilia activator are provided. The injury may be a traumatic brain injury (TBI). Related pharmaceutical compositions are provided.

The present application belongs to the field of control of pathogenic microorganisms and preparation of vaccines in aquaculture, and particularly relates to a method for preparing a bacterial pathogen inactivated vaccine based on irradiation technology and application. The present application adopts electron beam irradiation of pathogenic Aeromonas hydrophila to prepare a vaccine for preventing and treating Aeromonas hydrophila. The electron beam irradiation technology can inactivate the pathogenic bacteria in several minutes, maximally maintain the antigen conformation, realize complete removal of pathogenicity, and improve the immune recognition efficiency. The preparation method is safe, efficient, controllable, environmentally friendly, and has good industrialization expansion potential.

The present invention relates to the use of a therapeutic agent based on cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex for the preparation of a drug for the treatment of patients with active tuberculosis.

This application relates to bioabsorbable cationic steroidal antimicrobial (CSA) compounds or salts thereof having a structure of formula I, II or III: formula (I), formula (II) or formula (III), wherein R1-R 18 At least one of them (e.g., R) 18 This includes monoglycerides or diglycerides of fatty acids linked by ester bonds, and R1-R 18 At least one of them (e.g., R3, R7, and R) 12 ) is an amino acid linked to the steroid backbone via an ester bond or an amide bond, wherein: R 18 It has the following structure: -R 19 -(C=O)-O-C-CR 20 -CR 21 , where R 19 The radical is omitted or selected from alkyl, alkenyl, ynyl, and aryl, and R 20 and R 21 Independently selected from hydroxyl, alkylcarboxyl, and aminoalkylcarboxyl groups, provided that R 20 and R 21 At least one of them is an alkyl carboxyl group, R3, R7 and R 12 It has the following structure: R 24 R 23 N-R 22 -(C=O)-X-, where R 22 It is a substituted or unsubstituted alkyl group, X is oxygen or nitrogen, and R is... 23 and R 24 It is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl. (I)(II)(III)

This invention provides the application of Liu Mo Tang freeze-dried powder in the preparation of products regulating intestinal flora imbalance, belonging to the field of biomedical technology. The Liu Mo Tang freeze-dried powder provided by this invention effectively improves intestinal flora imbalance, particularly in constipation-predominant irritable bowel syndrome (IBS). Constipation-predominant IBS leads to a decrease in butyrate-producing bacteria, reduced butyrate production capacity, impaired intestinal barrier function, increased permeability, and weakened intestinal motility, accompanied by pathogenic bacterial proliferation. After administration of Liu Mo Tang, the abundance of butyrate-producing bacteria is upregulated, and the increase of abnormal bacteria is inhibited, which helps restore intestinal butyrate supply, improves intestinal barrier function, and promotes the recovery of intestinal motility. By reshaping the balance between butyrate-producing bacteria and pro-inflammatory bacteria, it effectively improves intestinal flora imbalance in IBS.

The application belongs to the technical field of microorganisms, and provides crocodile-derived lactobacillus salivarius and application thereof. The crocodile-derived lactobacillus salivarius is named lactobacillus salivarius H7 Ligilactobacillus salivarius H7, which was preserved in China Center for Type Culture Collection (CCTCC) on January 30, 2026, and the address of the preservation center is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M 2026301. The lactobacillus salivarius H7 has in-vivo and in-vitro antibacterial activity of preventing infection of zebrafish model organisms of aeromonas dhakini, and has a good application prospect in aquaculture.

Compositions for use in preventing or treating an infection of the nasal passages, sinuses, or both of a subject are described. The compositions include one or more peptoid compounds in an amount effective to prevent or treat the infection in the nasal passages, sinuses, or both. The compositions include the one or more peptoid compounds in an amount effective to inhibit one or more pathogenic bacteria, pathogenic fungus, or pathogenic virus in the nasal passages, sinuses, or both, while having relatively little or no activity against commensal bacterial species, commensal fungal species, commensal viral species, or any combination thereof, in the nasal passages, sinuses, or both of the subject.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

The application discloses a depolymerase for decomposing Klebsiella pneumoniae colanic acid and application thereof. The application obtains a novel colanic acid depolymerase Depo-K57-ZJ by separation, purification and identification from a Klebsiella pneumoniae bacteriophage, and the enzyme can efficiently decompose and destroy colanic acid of at least seven different colanic acid serotypes of Klebsiella pneumoniae, such as K2, K20, K39, K54, K57, K62 and K64. The application is expected to provide a candidate drug for solving the infection treatment of Klebsiella pneumoniae drug-resistant strains by developing and synthesizing the depolymerase Depo-K57-ZJ with the ability of degrading Klebsiella pneumoniae colanic acid.

The present invention relates to a combination of a first vaccine containing a non-replicating immunogen of Erysipelothrix rhusiopathiae and a non-replicating immunogen of porcine parvovirus, and a second vaccine containing a non-replicating immunogen of Leptospira bacteria, for use in the prophylactic treatment of pigs against Erysipelothrix rhusiopathiae infection, porcine parvovirus infection, and Leptospira bacteria infection, by injecting the first vaccine and the second vaccine separately into the dermis at a first injection site and a second injection site, respectively, in association with each other.

The present invention relates to novel compounds and formulations. Additionally, the present invention relates to novel compounds and formulations useful for pneumococcal and pneumococcal conjugate vaccines. More specifically, the present invention relates to compositions comprising a pneumococcal conjugate and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or pharmaceutically acceptable salts thereof, formulated as a stable nanoemulsion (referred to herein as an "SNE adjuvant composition" or "SNE").